Natixis Partners advised Laborizon’s shareholders in the sale of a majority stake to Biogroup

The shareholders of Laborizon, one of the major players in medical biology in France, sold a majority stake to Biogroup. Created in 2016 by the merger of 5 SELAS with the support of BPIfrance and its management team, Laborizon operates 105 sites located in the western part of France and in Ile-de-France. Over the last 4 years, Laborizon acted as one of the major market consolidators, more particularly in the western part of France, with more than 15 acquisitions, thus enabling the Group to become an undisputed player in the French “Grand-Ouest” and having access to the Ile-de-France region. Over the same period, the Group doubled in size to achieve total sales of more than € 150m. The acquisition of Laborizon will enable Biogroup, a major player in medical biology in France with approximately 700 sites, to continue its development in Centre-Val de Loire and Brittany regions and to strengthen its presence in Pays de la Loire. Following the sale of Cerba in 2017 and Biopath/SFMTBIO/POLIBIO in 2018, this transaction demonstrates further the expertise of Natixis Partners' teams in transactions involving medical biology groups.